Latest News

• share
• favorite_border

The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recently published studies in basic, translational and clinical cancer research from MD Anderson experts. Current clinical advances include combination therapies for thyroid cancer and multiple myeloma, as well as discoveries to improve CRISPR/Cas9 gene editing, to identify biomarkers for immunotherapy response, to utilize T cell therapy for osteosarcoma and to understand of the role of LIP-1 in regulating ERK signaling.

• share
• favorite_border

In honor of their notable contributions to the field of cancer research, Juan Fueyo, M.D., and Victor Prieto, M.D., Ph.D., from The University of Texas MD Anderson Cancer Center, have been named fellows of the American Association for the Advancement of Science (AAAS). Being named an AAAS Fellow is among the highest honors in the scientific research community.

• share
• favorite_border

MD Anderson and Yingli Pharma today announced a five-year strategic alliance to advance multiple oncology programs from preclinical discovery through clinical development.

• share
• favorite_border

Researchers from MD Anderson and Northwestern University have identified natural extracellular vesicles containing the ACE2 protein in the blood of COVID-19 patients that act as decoys to block infection from SARS-CoV-2

• share
• favorite_border

MD Anderson and Eisbach Bio have announced a strategic collaboration to jointly discover and develop new drugs that target synthetic lethal vulnerabilities in cancer.

• share
• favorite_border

The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recently published studies in basic, translational and clinical cancer research from MD Anderson experts. Current advances include an anti-CD19 chimeric antigen receptor (CAR) T cell therapy to treat follicular lymphoma, targeted therapies for urothelial cancers and advanced breast cancers, understanding the tumor microenvironment and immune landscape in pancreatic cancer, a link between depression risk and androgen deprivation for prostate cancer, and the discovery of new therapeutic targets for Alzheimer’s disease, liver cancer and aggressive breast cancer.

• share
• favorite_border

A blood test, combined with a risk model based on an individual’s history, more accurately determines who is likely to benefit from lung cancer screening than the current U.S. recommendation.

• share
• favorite_border

In patients with untreated, advanced melanoma, the combination of immune checkpoint inhibitors relatlimab and nivolumab doubled the progression-free survival benefit compared to nivolumab alone, with a manageable safety profile.

• share
• favorite_border

Patients with melanoma who reported eating more fiber-rich foods when they began immunotherapy treatment survived longer without cancer growth than patients with insufficient dietary fiber intake, according to new research from The University of Texas MD Anderson Cancer Center published today in Science.

• share
• favorite_border

The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recently published studies in basic, translational and clinical cancer research from MD Anderson experts. Current discoveries include the functional role of collagen in bone development and disease, molecular determinants of lung cancer histology, a role for long noncoding RNAs in breast cancer metabolism, a new regulatory factor in hypoxia-induced metastasis, and understanding how human papillomavirus (HPV) integration contributes to cancer development.

• share
• favorite_border

Combination therapies including venetoclax and another therapy have displayed promising results against subtypes of acute myeloid leukemia (AML) that are particularly difficult to treat, including relapsed or refractory AML with a specific mutation, high-risk AML and treated secondary AML. Researchers from The University of Texas MD Anderson Cancer Center presented numerous studies involving venetoclax combination therapy for AML at the 2021 American Society of Hematology (ASH) Annual Meeting.

• share
• favorite_border

Three clinical studies led by researchers at The University of Texas MD Anderson Cancer Center demonstrated enhanced responses for patients with high-risk lymphoma treated with axicabtagene ciloleucel (axi-cel) chimeric antigen receptor (CAR) T cell therapy. These results were reported at the 2021 American Society of Hematology (ASH) Annual Meeting.

• share
• favorite_border

The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recently published studies in basic, translational and clinical cancer research from MD Anderson experts. Clinical advances include positive data with targeted therapies for HER2 exon 20 mutant lung cancer, for older patients with mantle cell lymphoma and for BRAFV600E-mutant gliomas. Additional discoveries include insights into chromosomal instability and immunotherapy resistance in pancreatic cancer, the genomic landscape of small-cell lung cancer, hematopoietic stem cell decline with telomere shortening, identifying tumor suppressors in CRISPR screens, and physiological responses to fasting.

• share
• favorite_border

Results from a Phase II trial led by researchers at The University of Texas MD Anderson Cancer Center showed that treatment with belzutifan, a small-molecule inhibitor of hypoxia-inducible factor (HIF)-2a, achieved strong clinical activity in patients with renal cell carcinomas (RCC) and non-renal cell carcinoma neoplasms associated with von Hippel-Lindau (VHL) disease. The study was published today in the New England Journal of Medicine.

• share
• favorite_border

Researchers discovered that antihistamines are associated with improved responses to immunotherapy. Their work revealed a role for the histamine receptor in suppressing T cell activation to block anti-tumor immune responses.

• share
• favorite_border

The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recently published studies in basic, translational and clinical cancer research from MD Anderson experts. Current advances include discovering a new protein that regulates the DNA damage response, evaluating immunotherapy plus cryoablation to treat metastatic kidney cancer, identifying radiosensitizer targets to improve radiation therapy response, personalizing treatment intensity for acute myeloid leukemia, and identifying T cell features that play a role in response and resistance to cell therapy in leukemia.

• share
• favorite_border

This special edition of MD Anderson's Research Highlights features presentations at the Society for Immunotherapy of Caner 36th Annual Meeting.

• share
• favorite_border

Combination treatment with immune checkpoint inhibitors nivolumab and ipilimumab demonstrates overall survival for patients with melanoma that has spread to the brain, according to Phase II study results published today in The Lancet Oncology by researchers from The University of Texas MD Anderson Cancer Center.

• share
• favorite_border

The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recently published studies in basic, translational and clinical cancer research from MD Anderson experts. Current advances include the cost-effectiveness of expanded lung cancer screening criteria, a novel biomarker for predicting immunotherapy responses, development of a technique for multiplex single-cell chromatin profiling, combination immunotherapy for bone metastatic prostate cancer, understanding drivers of lung cancer metastasis, and enabling new T cell therapies for treating COVID-19.

• share
• favorite_border

In a new single-arm study, researchers at The University of Texas MD Anderson Cancer Center reported that radiation therapy as monotherapy is a safe and effective noninvasive treatment for oligometastatic renal cell carcinoma (RCC). The findings were published today in The Lancet Oncology

• share
• favorite_border

This special edition features oral presentations by MD Anderson researchers at the 2021 American Society for Radiation Oncology (ASTRO) Annual Meeting (Oct. 24-27) on novel therapeutic and diagnostic approaches, including partial breast irradiation, evaluating PD-L1 levels as biomarkers to better predict response to immunotherapy, and deep learning and biomechanical models.

• share
• favorite_border

The University of Texas MD Anderson Cancer Center celebrates its sixth annual Boot Walk to End Cancer® on Saturday, Nov. 6. Due to ongoing COVID-19 precautions, the 1.2-mile walk will be held virtually to keep participants, their families and their communities safe. Participants are encouraged to walk a personalized route in their own neighborhoods, whether it be on a trail, track or sidewalk. Registration is open at mdanderson.org/bootwalk.

• share
• favorite_border

The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recently published studies in basic, translational and clinical cancer research from MD Anderson experts. Current advances include new targeted therapy approaches for chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML), predicting survival following follicular lymphoma treatment, understanding how AML responds to checkpoint blockade therapy, identifying disparities in colorectal cancer screening, pregnancy outcomes following surgery for early-stage cervical cancer, and the discovery of a novel SHP2 targeted therapy.

• share
• favorite_border

Early data from a biomarker-driven Phase I trial of ATR inhibitor RP-3500 shows encouraging results for patients with advanced solid tumors harboring selected molecular alterations

• share
• favorite_border

MD Anderson and Schrödinger, Inc. announced a two-year strategic research collaboration to optimize the development of Schrödinger's WEE1 inhibitor program, designed to target the WEE1 kinase.

• share
• favorite_border

The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recently published studies in basic, translational and clinical cancer research from MD Anderson experts. Current advances include promising clinical results for therapies targeting HER2, FGFR and TGF- β, discovering new drivers of lung cancer development, novel approaches to predict immune responses and overcome immunotherapy resistance, and a novel combination therapy for prostate cancer.

• share
• favorite_border

The University of Texas MD Anderson Cancer Center today named Caroline Chung, M.D., associate professor of Radiation Oncology and Diagnostic Radiology, the new vice president and chief data officer (CDO), effective Oct. 1.

• share
• favorite_border

MD Anderson and the Rare Cancer Research Foundation have announced a collaboration to accelerate the development of new treatments for rare cancers by empowering all patients to contribute tumor samples for translational research efforts.

• share
• favorite_border

MD Anderson and Siemens Healthineers have announced the collaborative development of an education program focused on enabling the implementation of consistent, high-quality MRI in radiation oncology.

• share
• favorite_border

MD Anderson and BostonGene today announced a strategic alliance to advance the development and clinical integration of multiplatform biomarker signatures.

• share
• favorite_border

The University of Texas MD Anderson Cancer Center is proud to support World Cancer Research Day, Sept. 24, and its efforts to promote cancer research as a driving force behind progress in cancer prevention, early detection, treatment and survivorship.

• share
• favorite_border

Breast cancer survivors who participated in Active Living After Cancer, an evidence-based 12-week group program, markedly increased their physical activity and ability to accomplish the basic pursuits of daily life, researchers from The University of Texas MD Anderson Cancer Center reported today in Cancer.

• share
• favorite_border

The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recently published studies in basic, translational and clinical cancer research from MD Anderson experts. Current advances include a new method to measure breast cancer response, a new immunotherapy approach for multiple myeloma, characterization of the immune landscape of cholangiocarcinoma, a new contrast agent to improve molecular imaging techniques, and new treatment targets in breast, gynecologic and pancreatic cancers.

• share
• favorite_border

A study led by researchers from The University of Texas MD Anderson Cancer Center showed a significant overall survival benefit with ribociclib plus endocrine therapy for postmenopausal patients with hormone receptor-positive (HR+) human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer. This is the first demonstration of a survival advantage with a front-line CDK4/6 inhibitor in postmenopausal patients with HR+/HER 2- advanced breast cancer.

• share
• favorite_border

The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent studies in basic, translational and clinical cancer research from MD Anderson experts. This special edition features oral presentations by MD Anderson researchers at the virtual European Society for Medical Oncology (ESMO) Congress 2021 on novel therapeutic approaches, including cell therapy for solid tumors, antibody drug conjugates targeting TROP2 and neoadjuvant pembrolizumab for advanced solid tumors with mismatch repair deficiencies.

• share
• favorite_border

A new study in Science finds that pancreatic cells display an adaptive response to repeated inflammation that initially protects against tissue damage but can promote tumor formation in the presence of mutant KRAS.

• share
• favorite_border

MD Anderson to honor the life of trailblazing oncologist Emil J Freireich, M.D., in a virtual tribute event on Sept. 23

• share
• favorite_border

Researchers from The University of Texas MD Anderson Cancer Center have discovered that grouping epidermal growth factor receptor (EGFR) mutations by structure and function provides an accurate framework to match patients with non-small cell lung cancer (NSCLC) to the right drugs.

• share
• favorite_border

A new study from researchers at The University of Texas MD Anderson Cancer Center showed that stereotactic ablative radiotherapy (SABR) was as effective as surgery at providing long-term benefits to patients with operable early-stage non-small cell lung cancer (NSCLC) and generated minimal side effects. The study is the first of its kind to compare long-term results of SABR against surgical treatment in patients with operable early-stage NSCLC.

• share
• favorite_border

MD Anderson and SNIPR BIOME have announced a strategic collaboration to advance next-generation CRISPR-based microbiome therapies to reduce immune-related side effects in patients treated with immune checkpoint inhibitors.

• share
• favorite_border

The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recently published studies in basic, translational and clinical cancer research from MD Anderson experts.

• share
• favorite_border

The University of Texas MD Anderson Cancer Center and Bellicum Pharmaceuticals, Inc. today announced a global option and license agreement covering certain intellectual property and technology rights regarding Bellicum’s CaspaCIDe® (inducible caspase-9, or iC9) safety switch and related technologies, and the use of rimiducid, an agent used to activate the safety switch.

• share
• favorite_border

Omer Sultan joins MD Anderson as new Chief Financial Officer